|
Novavax inc (NASDAQ: NVAX) |
|
Novavax inc
NVAX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Novavax Inc's sales fell
by -69.69 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1677
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.61 %
Novavax Inc net loss decreased from $-178 millions, to $-81 millions in IV. Quarter 2024,
• More on NVAX's Growth
|
|
Novavax Inc realized a net loss in trailing twelve months.
Novavax Inc realized cash reduction of $ -0.25 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.69.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.52.
• More on NVAX's Valuation
|
|
|
|
|
Novavax Inc realized net loss in trailing twelve months.
Novavax Inc realized cash outflow of $ -0.25per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.69.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.52.
• More on NVAX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com